Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
Replidyne, Inc. today announced results from three Phase I trials studying REP8839, a novel topical antibiotic that has shown potent in vitro activity against major skin pathogens including methicillin-resistant S. aureus (MRSA). The results of the Phase I trials show that topically applie...Replidyne Provides Strategic Update
... inhibition program. As a result of prioritizing these preclinical programs, Replidyne has suspended the development of topical antibiotic rep8839 due to the additional investment required to optimize the formulation and the niche market opportunity. -- Development strategy for faropenem. R...Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
... of the Phase I trials show that topically applied rep8839 appears safe, well-tolerated and associated with l...hase II trials to study the safety and efficacy of rep8839 in patients with impetigo and other skin and wound infections." rep8839 was tested in three Phase I trials which collectiv...Replidyne Announces Second Quarter 2008 Results From Operations
...eplidyne's discovery research programs, primarily the C. difficile and DNA replication inhibition programs, offset by decreased expense related to the rep8839 program that was suspended in December 2007. Sales, general and administrative expenses for the second quarter of 2008 were $4.7 million compared to...Replidyne Announces 2007 Fourth Quarter and Full Year Results
...lidyne's discovery research programs, primarily its C. difficile and inhibition of DNA replication programs offset by decreased expense related to the rep8839 program that was suspended in December 2007. Research and development expense was $43.3 million for the full year 2007 compared to $38.3 million in 20...